Small molecules with copper chelating properties

DepYmed is focused on developing innovative therapeutics that target protein tyrosine phosphatases, specifically the enzyme PTP1B, which plays a crucial role in various signaling pathways associated with multiple diseases. The company is advancing two orally bioavailable small molecules into clinical trials aimed at treating Rett Syndrome, Wilson Disease, and certain cancers. Additionally, DepYmed is building a library of selective PTP1B inhibitors, which hold promise for addressing other significant metabolic, inflammatory, and neurodegenerative conditions.

In its therapeutic development efforts, DepYmed has also created a portfolio of novel small molecules with copper-chelating properties, which may serve as potential treatments for diseases such as Wilson Disease and cancer. By harnessing the potential of phosphatase inhibitors, the company aims to provide new therapeutic options for patients suffering from rare diseases and various forms of cancer, thereby contributing to advancements in the field of targeted therapies.

United States

DepYmed is currently developing potent inhibitors of the enzyme PTP1B as therapeutics for cancer and rare diseases. In addition, DepYmed has developed a portfolio of novel small molecules with copper chelating properties that can be applied as potential therapeutic agents for multiple diseases including Wilson Disease and cancer. ​

DepYmed

Company Details